Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOLMite dose-ranging placebo-controlled trial in house dust mite allergic rhinitis
2024-518519-20-01Phase 2Authorised
- Sponsor
- Laboratorios Diater
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MOLMite in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma (4 arms), sponsored by Laboratorios Diater. Primary endpoint: Threshold dose for positive conjunctival provocation test. Planned start Mar 2025; status: authorised.
02
Drugs
MOLMite
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2024-518519-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518519-20-01.